The home for drug-focused research
Adis is a leading international publisher of drugs-focused content.
A portfolio of over 30 peer-reviewed medical journals spanning all therapeutic areas, and a newsletter on drug safety.
What we offer
Services built around your paper.
From a first pre-submission check to interactive features that carry your findings further, everything is designed to ensure sound science is published and discovered.
Innovative article types
Podcasts, patient perspectives, and practical clinical guidance.
Learn more →VIP service
An offering available for the Premier journals. First decision in 15 days, guaranteed. Published in 30 days.
Learn more →Rapid+ journals
Peer review in as little as two weeks, with a dedicated personal contact who can style and submit on your behalf and ensure a timely, personalized and responsive service.
Learn more →The portfolio
Find your journal.
32 peer-reviewed titles across every therapeutic area, in three publishing routes.
Premier Journals
Our established, high-impact flagship titles.
Rapid+ Journals
The same rigour, with faster decisions.
Open Access Journals
Free for anyone to read on publication.
Other publicationsAdis also publishes 2 titles outside the journal portfolio
Drug-safety newsletterReactions WeeklyA weekly round-up of adverse drug reaction news, covering labelling changes, drug withdrawals on safety grounds, adverse reaction research and current issues in drug safety. Content is drawn from journals, scientific meetings, media releases and regulatory agency bulletins.View on Springer Nature Link →
Review journalHigh Blood Pressure & Cardiovascular PreventionAn international forum for original research, reviews, expert commentary, and consensus guidance on hypertension, cardiovascular prevention, and cardiovascular disease management. Published in partnership with the Italian Society of Hypertension.View on Springer Nature Link →Titles you may already know.
Premier JournalAmerican Journal of Clinical Dermatology
Evidence-based therapy and patient management in dermatology
Premier JournalClinical Pharmacokinetics
Disposition and clinical pharmacology
Premier JournalCNS Drugs
Drug treatment of psychiatric and neurological disorders
Premier JournalDrug Safety
Pharmacovigilance and medication safety
Premier JournalDrugs
Optimum pharmacotherapy across clinical pharmacology and therapeutics
Premier JournalTargeted Oncology
Precision medicine and biomarker-driven cancer therapy
Clinically Relevant Drug Insights Across All Therapeutic Areas
Adis Drug Reviews.
The Adis Drug Review program provides readers with the most important and clinically relevant information on the properties of new and established drugs, across all therapeutic areas.
Who it's for
Supporting the entire research community.
For authors
Fast, fair review and personalised support from first enquiry to publication.
Explore our portfolio →
For readers
Stay current with the latest evidence in drug development and clinical science.
Browse journals →
For librarians
Access, usage, and open-access support for your institution.
Access options →Part of Springer Nature
Global reach. Personal touch.
As part of Springer Nature, we support a global audience working in the pharmaceutical and biotech industry; medical research, practice and teaching; drug regulation and reimbursement; and adjacent markets such as finance and consulting.
“Efficient, timely, and professional from start to finish.”
Author
“Easy submission, relevant review comments, very high standards.”
Editorial board member and author
“The time from submission to online publication is phenomenal.”
Pharmaceutical funder